X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
TNP-2092 is a multi-targeting drug conjugate, exerting its antibacterial activity by inhibiting three essential targets RNA Polymerase, DNA Gyrase and Topoisomerase IV.
Lead Product(s): TNP-2092
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: TNP-2092
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 23, 2021
Details:
As part of the agreement, the parties plan to utilize a multitargeting drug conjugation platform developed by TenNor to discover new therapies for the treatment of nontuberculous mycobacteria (NTM) diseases.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 21, 2021
Details:
TenNor has completed a Phase II clinical trial for TNP-2092 in the United States for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) and received positive results.
Lead Product(s): TNP-2092
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 20, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
